Icahn Is Forest’s Latest Wolf At The Door
Executive Summary
Specialty pharma Forest Pharmaceuticals Inc. has already spent months fending off doubts about the future of its pipeline as well as a potential federal ban prohibiting its long-time CEO from negotiating federal contracts. Now, the company has a new wolf at the door: dissident investor Carl Icahn.